The new CDMO site introducing the most advanced and large -scale single -scale single -scale bioreactors in the region
Yokohama, Japan and Seattle – (Business Wire) –AGC BiologicsYour sympathetic CDMO expert, has announced today a strategic decision on high -scale technology that it will use in its new Yokohama, Japan installation. The CDMO introduces two single -use -single -use bioreactors Thermo Scientific Dynamic of 5,000 L, which makes the site one of the most advanced in Japan for large -scale organic production based on mammals, with GMP operations from 2027.
According to 2024 data from the BDO BIOTRAK database, single -use technology represents 51% of all mammal bioreactor technology on a global scale, exceeding the traditional stainless steel alternative. The attributes at the origin of this trend include fewer cleaning requirements, a cost barrier lower than the entry and a calendar for configuration, flexible configurations, a scalability to meet the changing demands of shorter clinical products and production times. AGC Biologics has the second largest global network of single -use manufacturing capacity in volume in industry, according to Biotrak. The new bioreactor technology guarantees that the company remains ahead of demand on the scale of the single -use systems industry.
“The new Yokohama site is designed to use single -use bioreactors to provide large -scale GMP manufacturing. The advanced Thermo Scientific technology makes this most advanced global network in Japan for large -scale manufacturing and still extends Christoph Winterhalter, business manager, AGC BUOLOGICS. “This location offers the capacity to meet the commercial needs of customers in Japan and Asia, as well as global customers who are looking for capacities using the latest technologies.”
“Flexibility and means of the production scale in a profitable way are essential for any therapy developer today, and CDMOs need the best possible technology to help them achieve them. Single-use technology thanks to our collaboration, ”said Daniella Cramp, main vice-president and president of the bioproduction activities of Thermo Fisher Scientific.
The new AGC Yokohama biological installation will provide support for initial process development work for early phase projects for late and commercial production. He will support the expression of mammals, cell therapy and messenger RNA (mRNA).
The installation of Yokohama should help maximize the efficiency of the operational and supply chain through the global network of the AGC Biologics by adding another site in the region. The CDMO is currently operating a site in Japan, its Chiba ease, Offering mammal expression and microbial fermentation services.
AGC Biologics is part of the AGC Inc. Life Science Society La Life Science Company operates more than 10 installations in the world focused on biopharmaceuticals, advanced therapies, pharmaceutical ingredients active in small molecules and agrochemicals.
To find out more about the global AGC organic service network for protein biologicals and cellular and genic therapies, please visit www.agcbio.com.
On AGC biologicals
AGC Biologics is a global organization and manufacturing organization of leading biopharmaceutical contracts (CDMO) with a high commitment to provide the highest level of service while we work side by side with our customers and partners, to provide friendly and expert services. We provide world development and manufacturing of therapeutic proteins based on mammals and microbials, plasmid DNA (PDNA), messenger RNA (mRNA), viral vectors and genetically modified cells. Our global network extends over the United States, Europe and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; And Chiba and Yokohama, Japan. We are currently employing more than 2,800 team members worldwide. AGC Biologics is part of the life of AGC Inc. life sciences The activity of the life sciences manages more than 10 installations focused on biopharmaceuticals, advanced therapies, active pharmaceutical ingredients of small molecules and agrochemicals. To find out more, visit www.agcbio.com.
Contacts
Contact with the media
Nick McDonald
AGC Biologics
nmcdonald@agcbio.com
AGC Inc. Multimedia Contact
info-pr@agc.com